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Abstract 
Helicobacter pylori (H. pylori) is a Gram-negative bacterium, usually acquired during childhood, 
whose natural habitat is the gastric lumen. H. pylori is accepted as the most important cause of gastritis 
and peptic ulcer in humans. Nevertheless, its important role in the pathogenesis of gastric cancer as 
well as in several extra-gastroduodenal diseases has been confirmed. The aim of this work is to discuss, 
for the first time in a single article, all publications concerning H. pylori infection arising from 
Piedmont region, Italy, where in 1893 Giulio Bizzozero was the first who observed and described spiral 
organisms in the stomach of animal models. A systematic review of all publications on the 
management of H. pylori in adults in Piedmont, based on a PubMed and a Scopus research from 1965 
to 2017 was performed. The discussed aspects are the epidemiology, the study on gastric and 
extragastric diseases related to H. pylori, the diagnostic methods, the treatment of H. pylori infection, 
and the possibility of reinfection. In conclusions, with almost 70 publications, Piedmont has proudly 
maintained the tradition of the father of the H. pylori. 
 
Key words: Cardiovascular - Cirrhosis – Culture – Diagnosis - Dyspepsia - Extragastric Diseases – 
Gastritis – Helicobacter - Peptic – Pre-eclampsia - Prevalence - Reinfection – Therapy - Ulcer 
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Helicobacter pylori (H. pylori) is a Gram-negative gastric bacterium “re-discovered” by Marshall and 
Warren in 1983.
1 
Giulio Bizzozero, a former University of Turin’ eminent professor, was the first who 
observed and described spiral organisms in the stomach of dogs and, though he did not realize what 
actually is known, he considered this finding important enough to publish it in 1893.2 Bizzozero could 
not suspect that this spiral-shaped bacterium will be the most widespread infectious agent of 
gastroduodenal diseases. In fact, he could not imagine that his observation will spark off an explosion 
of research, diagnostic tools, and developments of treatment protocols. 
   The aim of this “special article” is to do a systematic review of all original articles including adult 
patients managed for H. pylori infection, arising from Piedmont (the region of Turin). To identify all 
appropriate publications, a Pubmed and a Scopus search of all studies published from 1965 to 31 
December 2017 was conducted. Only original articles and letters were included and discussed. 
 
Epidemiology  
   Epidemiology of H. pylori infection in Piedmont, has been extensively studied in healthy subjects as 
well as in patients with several gastroduodenal or extra-gastroduodenal diseases. 
   The first study that reported the H. pylori seroprevalence in Turin (Torino), an industrial town in the 
Northwest of Italy, with a population of almost 1 million people, half of whom were born and lived in 
the South prior to transfer here, was conducted from April 1995 to July 1995 on 619 consecutive blood 
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donors attending the Molinette Hospital’s Blood Bank (Turin). H. pylori seroprevalence was assessed 
by presence of immunoglobulins G (IgG) against the bacterium in serum, by means of a commercial 
enzyme-linked immunosorbent assay (ELISA). The overall H. pylori seroprevalence was 47%: 51% in 
males, 27% in females (P < 0.001). According to the cohort-effect phenomenon, among subjects 
between 20-29 years of age, the seroprevalence in males was 29% versus 5% in females while at 40-49 
years increases to 56% in males versus 23% in females and at 50-59 years was 65% in males versus 
42% in females.
3
 
 
Gastroduodenal diseases 
Chronic gastritis and peptic ulcer 
   In a paper published by Di Napoli et al.,
 
before treatment all patients infected with H. pylori had 
chronic active gastritis. After eradication, the total score for gastritis decreased significantly (from 7.76  
to 3.22; P < 0.01, 95% CI = 2.94 to 5.28), while in non-responders the score was only slightly reduced 
(6.31; P > 0.1, CI = 0.57 to 3.32).
4 
   In 1993, the examination of serum samples of 82 dyspeptic patients undergoing endoscopy showed 
that patients with duodenal ulcers (DU) had significantly higher systemic IgG responses to a 
recombinant fragment of 128 kDa protein (the cytotoxin-associated gene A, CagA antigen) of H. pylori 
than  subjects with normal mucosa and chronic gastritis.5    
   In 1996, Bruno et al. enrolled 258 consecutive out-patients with active DU and histology-proven H. 
pylori infection. Upper gastrointestinal endoscopies (EGDS) were performed on entering the study, and 
then at two, six, and twelve months after the completion of the eradicating courses. Eradication 
produced a significantly higher ulcer healing rate at 2 months and no recurrence at 12 months.
6
 
   In 1996, Suriani et al. assessed whether H. pylori eradication performed after DU healing, could 
prevent ulcer relapse during a 2-year follow-up. After confirmation of both DU healing and H. pylori 
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infection, all patients were randomized to either the treatment or the placebo group and followed up. At 
the first endoscopy performed 3 months (± 2 SD) after antibiotic or placebo treatment, 16 patients 
(100%) in the treatment group and 5 patients (36%) in the placebo group were ulcer-free. After a mean 
22.6 months (19-27 months), only four patients (25%) in the treatment group experienced ulcer relapse.  
In contrast, 13 patients (92.9%) in the placebo group experienced relapse during follow-up. In this 
group 11 patients had already had a relapse after 6 months.
7
 
   In another study, 474 patients suffering from DU were recruited. After therapy, endoscopic follow-up 
provided controls at 6, 12, and 24 months and following controls stoppage in patients with healing H. 
pylori infection and without symptoms. H. pylori infection was verified histologically, serologically 
and, in the last period, with 13C urea breath test (UBT). In patients with DU recurrence, the protocol 
provided, until 1995-1996, the randomized long-term treatment with famotidine 20 mg/die or ranitidine 
150 mg/die; some patients were treated with seasonal modality. Later on, the management changed 
with the use of 20 mg omeprazole on alternate days or lansoprazole 15 mg/die for patients who did not 
benefit from the above treatment. Despite bacterial eradication, in this heterogeneous cohort with 
multiple causes of gastric damage, only 301/474 (63%) did not have DU recurrence or need for long-
term PPI assumption.
8
 
   In a prospective study, Pellicano et al. included 84 patients suffering from bleeding DU associated 
only with H. pylori infection. After bacterial eradication the authors observed a recurrence of DU in 3 
out of 46 (6.5%) patients who had stopped all medications and in 3 out of 38 (7.9%) patients under 
continuous long-term therapy with inhibitors of acid secretion. Hemorrhage did not recur during the 
period of observation in either group. No H. pylori reinfection was observed, as confirmed by the UBT, 
even in the six patients with DU recurrences. This confirmed that eradication of H. pylori is mandatory 
in patients who had an episode of bleeding from DU.
9
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   In a prospective study, 41 consecutive patients admitted to the Emergency Care Unit of Molinette 
Hospital for upper gastrointestinal (GI) bleeding were recruited. Serological diagnosis was performed 
by measuring antibodies both against H. pylori, by a commercial ELISA, and cytotoxic strains 
(Western Blot for anti-CagA, Vac-A, urease B, urease A). Due to the low sensibility of histology 
during GI bleeding, the search for H. pylori on biopsies was performed only during the follow-up. In 
case of doubt, either UBT or a stool antigen test were associated. Patients infected by H. pylori were 
treated, after hemodinamic stabilisation, with a triple therapy regimen including clarithromycin, 
amoxicillin and omeprazole (CAO). H. pylori eradication was evaluated after 3 months from the end of 
the therapy with UBT. Sixteen patients were infected from H. pylori (group A), 12 had only a history 
of non-steroidal antiinflammatory drugs (NSAIDs) consumption (group B), and 13 patients had both 
factors (group C). Thus, H. pylori infection was present in 29 out of 41 patients (71%). This rate of 
prevalence was higher than their control population, matched by age, admitted to the Emergency Care 
Unit for other diseases. Furthermore, 20 out of 29 patients (68%) were positive for anti-CagA and anti-
VacA antibodies. With respect to rebleeding within 72 h, it occurred more frequently in patients with 
H. pylori infection (groups A and C) than in those with only NSAIDs consumption.
10
  
 
Precancerous lesions and gastric cancer (GC)  
   Fifty-four patients with DU and H. pylori infection received eradication therapy. Endoscopic 
examination with antral and corporal biopsy was done at baseline and at yearly intervals. The follow-up 
period ranged from 60 to 144 months. H. pylori status was determined using a rapid urease test and 
modified Giemsa stain. After H. pylori eradication, glandular atrophy, detected at baseline in 17/24 
patients, disappeared in 5, improved in 2 and worsened in 3 cases. In addition, intestinal metaplasia 
(IM), presented at baseline in 12/24 patients was undetectable in 2 and persisted in the remaining 10 
cases. In the 14 patients in whom H. pylori infection persisted, glandular atrophy, disappeared in 2, 
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worsened in 2 and appeared in 5 patients. IM, detected at baseline in 1 case, appeared in other 5 cases 
(P < 0.01). After H. pylori eradication, atrophy grading did not show a significant improvement, 
although there was a general trend toward improvement in responder patients, while IM improved in 
5/12 (41%) patients and was not detectable in 2 cases. In contrast, IM appeared in 5/14 patients in 
whom H. pylori infection persisted. The authors concluded that, in a long-term follow-up, H. pylori 
eradication prevented the appearance of IM, whereas it did not affect glandular atrophy.
11
 
   Ponzetto et al.,
 
in 1996, reported the detection of antibodies anti-CagA of H. pylori in 96% of 51 
patients having surgery for GC versus 18% of the general population (patients admitted to the 
Hospital’s Emergency Care Department).12 
   Twenty patients with GC and H. pylori negative histology took part to another study. The control 
group consisted of H. pylori negative subjects, divided in adult patients (N: 19) and asymptomatic 
children (N: 20) with H. pylori negative fecal test. The adult controls suffered from past H. pylori 
infection, eradicated 10 years earlier, and DU. In this group, H. pylori negative assessment was 
performed every year by endoscopy and gastric biopsy specimens (the reason for this interval was not 
explained). CagA and VacA seropositivity was 90% and 95% in GC, 84% and 84% in DU H. pylori 
negative patients, 25% and 5% in H. pylori negative children, respectively. A significant difference was 
found between adults and children (P < 0.0001).13 The positivity to anti-CagA and anti-VacA, in 
patients with negativity to other tests, probably reflects an H. pylori infection before the appearance of 
GC, since it has been reported that CagA antibodies persist longer after eradication treatment than IgG 
anti-H.pylori.
14
 Similar data were subsequently confirmed by the same group in another study.
15 
 
   In two papers, Suriani et al. prospectively evaluated 2360 patients referred to the Endoscopy Unit of 
Rivoli Hospital. After exclusion of not eligible patients, a total of 1750 patients were studied by 
endoscopy and multiple biopsies. Type 3 IM was found in 6.7%; 709 patients had H. pylori on 
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histological examination. The presence of H. pylori was neither correlated to type 3 IM in the antrum 
(P = 0.99) nor to gastric atrophy (P = 0.1).16,17 
   In the context of a multicenter survey, a prospective case-control study of patients who had 
undergone surgery for GC was performed. Among patients, 82% were seropositive for IgG anti-H. 
pylori compared to 57% of controls (P < 0.0001). Moreover, 84% were seropositive for anti-CagA 
antibody versus 18% of controls (P < 0.0001). There was no difference between the frequency of H. 
pylori in intestinal type and diffuse type carcinoma.
18
 
   In a study, conducted in Rivoli and Naples, the authors using the immunohistochemical evaluation of 
5-methylcytosine (5-MC), assessed the global DNA methylation of gastric mucosa. The population 
consisted of 93 patients consecutively referred to the Digestive Endoscopy Unit of Federico II 
University of Naples because of dyspeptic symptoms. All patients underwent EGDS with eight biopsy 
specimens, five of which were processed for both histological and immunohistochemical evaluation 
and three for the rapid urease test. Furthermore, serum samples were collected to determine anti-H. 
pylori and anti-CagA antibodies. Forty-one surgical samples of GC tissues were obtained at the time of 
surgery and processed for both histological and immunohistochemical evaluation. To validate their 
results, the authors selected 54 cases of H. pylori-positive chronic atrophic gastritis with IM. Finally, 
they included 10 dyspeptic patients, enrolled at the Endoscopy Unit of Rivoli Hospital, with history of 
H. pylori eradication and followed up endoscopically; these patients had preneoplastic lesions (ie, 
atrophy and IM) and a family history (first-degree relative) of GC. According to H. pylori infection, the 
93 dyspeptic patients from Naples were subdivided into 47 H. pylori-negative subjects and 46 H. 
pylori-positive patients, 28 of whom were anti-CagA+. In the H. pylori-negative group, all subjects had 
normal gastric mucosa with a minimal infiltration of lymphomonocytes in the lamina propria. The H. 
pylori-positive patients were subdivided into two groups: 21 H. pylori-positive chronic gastritis, 10 of 
whom were CagA+, and 25 H. pylori-positive chronic atrophic gastritis, 18 of whom were Cag-A+. In 
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13/25 H. pylori-positive patients, chronic atrophic gastritis, atrophy was mild and restricted to the 
antrum, while it was moderate and diffuse to both antrum and angulus in the remaining 12 cases, 
regardless of the Cag-A status. Considering the evaluation of 5-MC, the authors found a gradual 
decrease in the global DNA methylation from H. pylori-negative to H. pylori-positive chronic gastritis, 
H. pylori-positive chronic atrophic gastritis and GC cases. These data suggest that DNA 
hypomethylation could be implicated in H. pylori-related gastric carcinogenesis at an early stage. 
Furthermore, the 5-MC immunopositivity was negatively correlated with markers implicated in cell 
cycle control such as Ki-67 and p53.
19
 Global DNA hypomethylation is generally considered one of the 
hallmarks of cancer cells because the genes vulnerable to aberrant hypermethylation usually are 
overlapped by the genes targeted by hypomethylation.20 During the 10-year follow-up the authors 
found a progressive decrease in global DNA methylation in patients with chronic atrophic gastritis, 
despite the successful H. pylori eradication. The latter, in subjects with preneoplastic lesions did not 
halt the gastric carcinogenesis process.
19
  
 
Gastric mucosa-associated lymphoid tissue (MALT) lymphoma 
   The presence of an organized lymphoid infiltrate in the lamina propria of gastric mucosa, so-called 
MALT, is considered an obligate precursor of MALT lymphoma.21 In a study published in 1997, the 
authors followed up 16 patients with B-cell oligoclonality. Nine of them had Sjogren’s syndrome, of 
which seven had primary and two had secondary syndrome associated with rheumatoid arthritis and 
scleroderma (first group). Two additional patients had rheumatoid arthritis, and one scleroderma 
(second group). Four patients had dyspepsia without an associated autoimmune disease (third group). 
Patients were followed up for a minimum of 3 months up to a maximum of 33 months (average 15.3 ± 
9.2). In 3 out of 12 patients initially positive for H. pylori the bacterium had not been eradicated at the 
time of the last biopsy. Only in one patient did B-cell clonality seemed to parallel H. pylori infection. 
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In most cases (8 of 10) in the 3 groups, clonality persisted for up to 33 months after bacterial 
eradication.22 
 
Other gastrointestinal conditions 
   To evaluate the prevalence of H. pylori infection in patients with inflammatory bowel disease (IBD) 
diagnosed for the first time, Pellicano et al. performed a pilot case-control study. Twenty patients were 
compared to 29 controls affected by idiopathic constipation. All were screened for the presence of H. 
pylori by UBT. H. pylori infection was shown in 60% of patients with IBD versus 41% among controls 
(P = 0.2).23 
   In a retrospective case-control study Simondi et al. evaluated the prevalence of H. pylori infection in 
patients with celiac disease (CD) or duodenal intraepithelial lymphocytosis (DIL). One hundred and 
fifty-four patients with a duodenal biopsy and a diagnosis of damage type 1, 2, or 3 according to 
Marsh-Oberhuber classification were included. As controls, subjects suffering from idiopathic 
constipation, without CD, were included. H. pylori prevalence in CD patients was 36% versus 19% in 
DIL patients and 41% in controls. Independently from the other variables considered, H. pylori 
prevalence in DIL patients was significantly lower compared to controls (P < 0.05).
24
 
   In a single-center study, the inclusion criteria were a diagnosis of lymphocytic or collagenous colitis 
and active H. pylori infection. The authors included 50 patients affected by microscopic colitis and in 
whom H. pylori status was assessed by histology (N: 47) or by UBT (N: 3). H. pylori resulted positive 
in 18 patients (36%), of whom 13 affected by lymphocytic colitis and 5 affected by collagenous colitis 
(P = 0.51). There was no difference in term of H. pylori infection comparing cases and controls (P = 
0.59). Nevertheless, considering patients with history of H. pylori positivity but with eradication before 
the diagnosis of microscopic colitis as patients with negative H. pylori status, there was a statistically 
significant difference between cases and controls (P = 0.006). The authors concluded that to be H. 
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pylori negative, ab initio or after antibiotic treatment, seemed to be a risk factor for the onset of 
microscopic colitis.25 
 
Extra-gastroduodenal diseases
 
   Since the last decades, several studies have reported on the link between chronic H. pylori infection 
and a variety of extra-gastroduodenal manifestations, based on potential mechanisms involving a low-
grade inflammatory state, molecular mimicry patterns, and interferences with the absorption of 
nutrients.
26 
Actually, although the Maastricht V/Florence Consensus Report of the European 
Helicobacter Study Group has considered causal associations of H. pylori only those with unexplained 
iron-deficiency anemia, idiopathic thrombocytopenic purpura (Grade A of recommendation) and 
vitamin B12 deficiency (Grade B of recommendation)
27 
other relationships could not be excluded. 
Several studies on this field, have been performed by Piedmont’s groups.  
 
Heart diseases 
   In 1995 Morgando et al. recruited 35 male and 7 female patients admitted to the Emergency Unit of 
Molinette Hospital in Turin with acute myocardial infarction (AMI). They used a commercial ELISA 
to measure H. pylori specific antibodies. The 198 controls were obtained from a cohort of 619 
consecutive patients admitted to the same Emergency Unit for other reasons. All 7 AMI patients aged 
50-59 years were positive to H. pylori compared with 50% of controls. However, at age 60 or more the 
association seemed less striking (86% versus 67% for men, 71 % versus 52% for women).
28 
The same 
group confirmed these findings in a series of studies.
29-31 
In a study performed in Turin and Sondalo 
(Northern Italy), 223 consecutive male patients admitted for AMI at the Coronary Care Unit were 
compared with 223 age-matched male patients admitted to the Emergency Care Unit. Cases and 
controls came from the geographical area of Northern Italy and had a similar socioeconomic status as 
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based on occupation and level of education. The seroprevalence of H. pylori was significantly higher 
among patients with AMI (84%) as compared to the control population (62%; P < 0.0001). The anti-
CagA antibodies were detected in 34% of the patients versus 27% of the controls (P = 0.17).32 
   Pellicano et al. investigated if H. pylori infection was associated with unstable angina (UA). Thirty-
two patients consecutively admitted for UA to the Coronary Care Unit of the Novi Ligure and Rivoli 
Hospitals were included. As controls, the authors selected 64 subjects admitted to the Emergency Care 
Unit for any reason (excluding cardiological causes), age and sex-matched (2 controls for each case). 
Cases and controls were from the geographical area of Northwestern Italy and had similar 
socioeconomic status judged on work type and on the level of instruction. They found that 81% of the 
patients with UA were seropositive, as compared with 53% among the control population (P = 0.007). 
Serum levels of cholesterol, glucose, and fibrinogen in plasma, presence of hypertension and 
socioeconomic status were comparable in both H. pylori seronegative and seropositive patients.
33
 
   To investigate the possible influence of H. pylori eradication on parameters involved in 
cardiovascular diseases, 496 patients with H. pylori-positive dyspepsia and/or peptic ulcer (DU, N: 80; 
gastric ulcer, N: 51) were studied up to five years. After H. pylori eradication, a significant trend 
towards increase for high-density lipoprotein cholesterol (from 48 to 52 mg/dL; P= 0.02) was observed. 
C-reactive protein (from 0.22 to 0.19 mg/dL) and fibrinogen (from 257 to 222 mg/dL) levels decreased 
in a significant manner (P < 0.0001). Body mass index (BMI)(from 25 to 27 kg/m2, P= 0.03) and 
diastolic blood pressure (from 85 to 89 mmHg, P = 0.04) increased gradually compared to baseline.
34
 
   In 2014, a multicenter study including Ponzetto A, reported data on 103 consecutive patients 
admitted during the year 2005 for ischemic heart disorders. H. pylori infection was determined 
serologically using an ELISA test and confirmed by western blotting. The latter was also used to detect 
the presence of anti-CagA antibodies in serum samples. A total of 41 patients (39.8%) were H. pylori 
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positive, and 19 of these (46.3%) had serum antibody to CagA. B-type natriuretic peptide median levels 
in H. pylori infected and uninfected patients were 601 pg/mL and 325 pg/mL, respectively (P = 0.18); 
median levels in infected CagA+ and CagA− patients were 781 pg/mL and 305 pg/mL (P < 0.01). 
Interleukin (IL)-6 median levels among infected and uninfected patients were 17 pg/mL and 7.7 pg/mL 
(P = 0.03), respectively. Tumor necrosis factor-α (TNF- α) median levels in infected and uninfected 
patients were 2.9 and 2.5, respectively (P < 0.01).
35
 
 
Liver diseases 
   In an initial study on cirrhotic patients, an ELISA method was used to assess the seroprevalence of 
anti-H. pylori IgG antibodies in 70 consecutive male hepatitis C virus (HCV) positive cirrhotic patients, 
and in a control population of 310 male age-matched blood donors from the same area. An immunoblot 
assay was also used to detect antibodies against the CagA antigen in sera. The prevalences of H. pylori 
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were 77% and 59% in patients and controls (P = 0.004), respectively. Cag-A positivity was observed in 
95% (57/60) of the patients versus 18% of the controls. The authors also analyzed resected liver tissues 
from 25 hepatocellular carcinomas (HCC): Helicobacter genomic sequences were detected in 23/25 
cases (92%). PCR with primers specific for the conserved region of the cag A gene of H. pylori was 
positive in 81%.
36
 This was the first worldwide report to show Helicobacter sequences in the liver of 
patients with HCC, published contemporarily with another paper of the Bordeaux' group.
37 
   Following this work, the same group showed that the prevalence of antibodies against H. pylori in  
cirrhotic hepatitis B virus patients was significantly higher than in controls (P < 0.001) and that there 
was no relationship between this prevalence and Child-Turcotte-Pugh’s class.38 Similar results was 
reported considering cirrhotic HCV-positive patients.39 On the contrary, the seroprevalence of 
antibodies against H. pylori in patients with chronic autoimmune hepatitis
40 
or with the formerly known 
primary biliary cirrhosis, now primary biliary cholangitis, was similar to that of controls.
41
 
   The presence of anti-H. pylori antibodies was evaluated in 46 consecutive cirrhotic HCV-positive 
patients and superimposed HCC, attending the Department of Gastro-Hepatology, Molinette Hospital 
of Turin.
 
The prevalence of antibodies to H. pylori was significantly higher (78.2%) in patients with 
HCC than (54%) in controls.
40 
To confirm this initial result, the same group analyzed liver samples 
obtained during the surgical excision from 23 patients operated upon for HCC superimposed on HCV-
related cirrhosis and from 6 patients suffering from metastatic cancers to the liver, in whom surgery 
might obtain remission of the disease. The authors found DNA sequences typical of Helicobacter spp. 
in 85% livers from patients operated for HCC using Helicobacter genus-specific 16S rRNA primers. 
Two of 6 liver samples obtained from patients whose livers were resected for metastasis due to colon 
cancer, contained sequences typical of Helicobacter spp.. Ninety-four percent of liver tissues from 
positive patients, when tested for Helicobacter genus, were also found positive when tested for the 
presence of a sequence that was typical for H. pylori, i.e., the cag A gene.43 
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Neurological diseases 
   One hundred three consecutive patients with migraine attending the Headache Center of the 
University of Turin, for the first visit, were enrolled in a study.
 
A group of 103 healthy subjects 
attending the Molinette Hospital’s Blood Bank, matched for sex and age, served as controls. H. pylori 
infection was assessed by means of both UBT and IgG against the bacterium in serum. H. pylori 
infection was present in 30.1% of the patients with migraine and 31.1% of the controls (P = NS). 
Morevover, this infection was not associated with any significant variation in the clinical features of the 
disease.44 
   Eighty consecutive patients aged less than 65 years, suffering from ischemic stroke presenting to the 
Neurological Ward of three Hospitals in Turin were recruited. Sex and age-matched blood donors (4 
controls for each case) served as controls. H. pylori infection was demonstrated in 80% of patients as 
compared to 59.4% of controls (P<0.001). The authors concluded that these results support the 
association between H. pylori infection and stroke.
45
 
 
Metabolism 
   Forty-one consecutive type 2 diabetic subjects attending an out-patient clinic in Turin participated in 
a study. Thirty-one healthy subjects matched for sex, age, and geographical area of residence served as 
controls. The UBT showed gastric H. pylori infection in 66% of diabetics and in 48% of controls (P < 
0.05). Nevertheless, microangiopathy was significantly more prevalent (P < 0.05) in H. pylori negative 
patients (85%) than in H. pylori positive patients (48%).
46
 
   Twelve patients with primary autonomic failure were studied. The results were compared with those 
of 31 healthy controls and 31 patients affected by type 2 diabetes without autonomic neuropathy. To 
assess the presence of H. pylori infection, all patients and controls underwent a UBT. H. pylori 
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infection was detected in 100% of autonomic failure patients, in 48% controls and in 71% diabetic 
patients; this difference was significant (P = 0.02).47 
 
Blood disease and systemic autoimmunity 
   Thirty-seven consecutive polycythemia vera (PV) patients, followed at the Hematological Unit of the 
Institute of Medical Science, were included. Seventy-three controls were selected from consecutive 
out-patients referred to the Department of Internal Medicine and to the Emergency Department for 
endoscopic examination, matched to patients (1 patient : 2 controls) for sex and age. All patients 
underwent EGDS with multiple gastric biopsies. The operator was blinded as to whether the patient had 
PV or belonged to the control group. Blood samples of patients and controls were obtained for serum 
anti-CagA and IgG antibody determination. H. pylori infection was more frequent in PV patients (83%) 
than in controls (57%) (P < 0.01). The prevalence of anti-CagA antibodies was also significantly higher 
in PV patients than in controls (66% versus 37%, P < 0.01).
48
 
   The presence of non-organ-specific autoantibodies (NOSAs) was evaluated in 49 consecutive patients 
suffering from DU and H. pylori infection (Group A) and 38 consecutive subjects affected with DU 
related to the consumption of NSAIDs, but not to the presence of H. pylori (Group B) and resident in 
the same area. A serum sample from each patient was tested to detect antinuclear (ANA), anti-smooth 
muscle (SMA), and anti-liver/kidney microsomal-1 (LKM-1) antibodies. ANA, SMA, and anti-LKM-1 
antibodies were present, respectively, in 10%, 4%, and none in Group A. In Group B, ANA was 
present in 8%, SMA in 8%, and anti-LKM-1 in none. The difference was not statistically significant.
49 
A recent study, with a similar design, including patients with gastric ulcer, obtained similar results.
50 
Pregnancy 
   A total of 167 serum samples from patients (118 male) with reproductive disorders, seen at two 
clinics for infertility in Turin and Siena were examined. As controls, sera from blood donors of similar 
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range of age and proportion male/female as the patients, living in Turin or Siena (N: 837) were 
examined. The H. pylori status was determined serologically using two tests, a commercially available 
ELISA and a Western blotting assay. The authors determined the presence of anti-H. pylori IgG, and 
that of specific IgA in 11 specimens of follicular fluid, 16 specimens of vaginal secretions, and 28 
specimens of semen obtained from some of the above-reported patients chosen at random. 
Seropositivity for H. pylori was significantly more common in patients than in age- and gender-
matched controls (49.1% and 33.5%, respectively, P = 0.0001).
51
 Despite these results, it is premature 
to state that the association between H. pylori infection and infertility is not coincidental. 
   In a very interesting study, pregnant women delivering at the Maternal–Fetal Medicine Unit of the 
University of Turin were recruited. Maternal blood samples were collected before delivery from 47 
consecutive pregnant women with diagnosis of pre-eclampsia (PE), and from 47 women with 
uneventful pregnancies, matched for maternal age. Twenty placentas were obtained from 10 of the PE 
pregnancies and 10 of the controls delivered by Cesarean section. Serum anti-H. pylori IgG and anti-
CagA were assessed. Detection of H. pylori DNA was carried out by a nested PCR. The two groups 
were comparable for maternal age, smoking habit, pre-pregnancy BMI, gestational weight gain, 
treatment with antibiotics and risk factors for PE. Among PE women, there were significantly more H. 
pylori seropositive subjects (51.1%) than in normal pregnant women (31.9%) (P = 0.03). Anti-CagA 
antibodies were significantly more common among PE mothers (80.9%) than among normal pregnant 
women (14.9%) (OR, 26.0; 95% CI, 8.19–82.7; P < 0.001). All samples, from each of the placentas 
tested (cases and controls), were negative for the presence of H. pylori DNA. The association was 
stronger in cases of CagA+ strains.
52
 This study presents direct evidence of an association between H. 
pylori infection and PE in Italian. A possible bias could arise from the lacking data of ethnic 
background of all women. The fact that all placentas were negative for H. pylori DNA indicates that 
the pathogenic mechanism would not be local. This finding, along with the knowledge that H. pylori is 
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predominantly acquired during childhood and that the infection is lifelong when untreated, elicits the 
speculation that H. pylori positive women may have underlying vascular damage; such subclinical 
dysfunction might augment the inflammatory changes of pregnancy, thus contributing to the symptoms 
of PE. CagA+ strains are associated with increased TNF-α levels.
53 
PE is equally characterized by an 
exaggerated inflammatory response: high leucocyte and neutrophil count, high levels of C-reactive 
protein and high levels of proinflammatory cytokines, such as TNF- α.
54 
These data were substantially 
confirmed by the same group
 
in a subsequent study.
55
 
 
Diagnostic methods 
   A total of 125 consecutive patients, either dyspeptic or with a previous history of peptic disease 
referring to GI Unit of Mauriziano Hospital of Turin, for H. pylori assessment by means of UBT, were 
included in a study.
 
Fresh stool specimens were collected within 1 week of 
13
C-UBT. Fecal H. pylori 
detection was performed by means of a commercially available kit that uses polyclonal anti-H. pylori 
antibodies (HpSA). Overall UBT was positive in 40 cases and negative in 85, while HpSA was positive 
in 71 cases and negative in 54. Hence, conflicting results were found in 30% of subjects; 34 out of 37 
cases presented a positive HpSA test in the presence of negative UBT. The discrepancy was mostly 
found in the group of “treated” patients. While a negative HpSA test correlates well with UBT, a 
certain degree of discrepancy can be appreciated in the presence of positive results, mainly in subjects 
evaluated after eradication treatment.
56
 This confirm the importance to use monoclonal tests when 
diagnosis of H. pylori infection is performed with a fecal test.
 21
 
   
UBT was administered to 91 patients attending the out-patient clinic of the Department of Gastro-
Hepatology (Molinette Hospital, Turin).
 
The presence of antibodies against H. pylori was tested both in 
serum and the saliva. A patient was considered infected when had at least two positive tests (gold 
standard). Saliva (Simplex™ H. pylori RAPID test, Analyte Diagnostics, Inc. Hallandale, Florida 
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USA) was collected by a sterile absorbent pad placed in the mouth and assayed immediately for H. 
pylori antibodies by an immunochromatographic method. There were 37 out of 91 gold standard 
positive patients, of which Simplex™ H. pylori RAPID test identified 29. Of 54 gold standard negative 
test, the salivary test falsely identified 13 as positive. Statistical analysis revealed a sensitivity of 
78.3%, a specificity of 75.9% and an accuracy of 76.9%.
57
 
   The first study in Piedmont that analyzed by culture the prevalence of H. pylori antibiotic resistance 
was published by Franzin et al. The methods used were the agar disk diffusion test and E-test, a 
technique for the quantitative determination of susceptibility to antimicrobial agents. Forty-nine 
patients were included. All the strains tested were susceptible to amoxicillin by both methods. Two 
strains were resistant to clarithromycin by the disk diffusion test and by E-test, and one strain was 
resistant only by E-test. In this study two strains were found to be clarithromycin-resistant by the disk 
diffusion method and three by E-test. Resistant pretreatment strains were found in two patients (5.9%) 
and a resistant posttreatment strain in one (2.9%), indicating acquired resistance.
58 
In a European 
multicentre study, including data from Turin, the primary rate of H. pylori clarithromycin resistance in 
Italy (2008-9) in adult patients resulted 26.7%.
59 
   To evaluate if in a clinical setting culture can be performed with a good accuracy, bioptic samples of 
patients who failed at least 3 courses of treatment were considered before to made the antibiogram for 
antibiotic resistance assessment. Out of 30 positive patients, culture correctly identified 29. In 1 case, 
no growth of micro-organisms was observed for up to 12 days. On the contrary, histology, serology and 
UBT gave a positive result. In addition, searching for antibodies against CagA in circulation, the strain 
of the bacterium was considered more virulent. Among specimens obtained from the control group, 
bacterial culture accurately identified all negative samples. Statistical analysis revealed sensitivity of 
97%, specificity of 100%, and accuracy of 98% for bacterial culture. Positive and negative predictive 
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values were 100% and 94%, respectively.
60 
Thus, also in a clinical setting this procedure provides a 
good level of diagnostic accuracy. 
   In a multicentric study including patients with functional dyspepsia, the authors prospectively 
evaluated the symptomatic benefit of treatment with a food supplement composed of sodium alginate, 
carbonate calcium, pineapple, papaya, ginger, α-galactosidase and fennel (Perdiges, Bioten Snc, Turin, 
Italy), after H. pylori treatment.
 
The primary goal was to establish the percentage of patients who 
continued to abstain from PPI as they waited to carry out the UBT, differentiating between patients 
who were treated (N: 55) with Perdiges and those who were not (N: 36). All the patients treated with 
Perdiges (100%) and 86% of the patients who were not (P = 0.008) continued to abstain from PPI in 
the period awaiting the UBT.61 This could allow to reduce the need for antisecretive drugs. 
 
Treatment of H. pylori infection 
   In 1992, Di Napoli et al. treated for 10 days 50 consecutive patients with H. pylori positive non-ulcer 
dyspepsia, with colloidal bismuth subcitrate (CBS), tinidazole and amoxicillin. Infection was 
confirmed by histological evaluation of four antral biopsy specimens taken during endoscopy, and by a 
positive urease test. The same evaluations were performed six weeks after treatment. At the second 
endoscopy 33 patients out of 48 (69%) gave a negative result to the urea test and there was no 
histological evidence of H. pylori infection.4 
   Bologna et al.
 
compared the ability of 4 different regimens of CBS in combination with one or two 
antibiotics to eradicate H. pylori. A total of 140 consecutive patients with histological evidence of H. 
pylori infection on antral biopsies were included in the study. The treatment groups were: a) CBS with 
amoxicillin and tinidazole b) CBS with ofloxacin c) CBS with ofloxacin and amoxicillin d) CBS with 
metronidazole. Although higher eradication rates (Table 1) were achieved in group d, the difference did 
not reach statistical significance.62 
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   Suriani et al. treated with ranitidine, metronidazole, doxycycline, and CBS for 2 weeks 16 patients 
with a history of DU healed by H2-receptor antagonist therapy and with H. pylori positivity at 
histological tests: the therapy eradicated H. pylori in 81% of cases.7  
   In another study
 
126 patients shown infected by H. pylori were treated with CAO or MAO 
(metronidazole 250 mg q.i.d., amoxicillin 500 mg q.i.d and omeprazole 20 mg b.i.d.) regimens for 10 
or 14 days. Diagnosis of H. pylori infection was assessed by histology and serological evidence of 
raised levels of IgG against the bacterium at 3, 6, 12, 24 months (Table 1). No statistical difference was 
demonstrated between the two regimens as well as between the two periods.
63
 
   In 1999, 37 naïve patients with H. pylori positive gastritis were treated with lansoprazole, 
amoxicillin, plus azithromycin for 3 days starting from the second day of treatment (Table 1). H. pylori 
eradication rate on per-protocol (PP) basis was 54%.
64 
   In the Fanzin’ study
 
10 patients were treated with bismuth salts (CBS: 240 mg four times a day) and 
omeprazole (20 mg a day) (CBSO) for 2 weeks. Other 39 subjects were treated with the triple therapy 
CAO for 1 week. PP eradication rate was 90% (28/31) for patients treated with CAO and 67% (4/6) for 
patients who received CBSO.
58
 
   In two studies, patients referred to the Unit of Gastroenterology at Mauriziano Hospital (Turin) for 
the assessment of H. pylori status were evaluated to analyze eradication rate after treatments prescribed 
by generalists. The eradication rates for first-line H. pylori eradication therapies adopted by family 
doctors are reported in Table 1.
65,66 
   In the study by Rocco et al. 54 consecutive patients with DU and H. pylori infection were treated 
with CAO regimen: sixteen patients dropped out during the follow-up, 24 responded to eradication 
therapy, whereas H. pylori persisted in the remaining 14.
11 
   A total of 172 patients were randomly treated with a triple therapy regimen comprising proton pump 
inhibitor (PPI), amoxicillin and clarithromycin: 66 patients received a 1-week triple therapy (group I), 
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42 subjects a 10-day triple therapy (group II) and 64 a 14-day triple therapy (group III). H. pylori 
infection and the outcome of eradication treatment, were assessed by UBT and histology. The overall 
H. pylori eradication rate was 68% in group I, 76% in group II and 72% in group III, without any 
statistically significant difference.
67
 
   A total of 159 patients, with a documented history of recurrent DU, were randomly treated with a 
triple MAO regimen. In detail, 53 patients received a one-week course (Group I), 53 subjects a 10-day 
course (Group II) and 53 others a 14-day course (Group III). H. pylori infection was assessed by UBT 
and histology. At the end of the course of treatment, the overall H. pylori eradication rate in the PP 
analysis showed no statistical differences, with an eradication rate of 74% in group I, 76% in group II 
and 78% in group III.68 
   In a randomized study the efficacy of eradication treatment, using metronidazole versus tinidazole, in 
subjects never treated for H. pylori, was evaluated.
 
Diagnosis and eradication of H. pylori infection 
were assessed by UBT. A total of 171 patients was treated: 91 of them with  a MAO regimen and 80 
with tinidazole, amoxicillin and omeprazole regimen for 7, 10 or 14 days. No difference was found 
between the two regimens as well as between the two periods.
69
  
   Reviewing the charts of naïve patients underwent UBT in the outpatient clinic of Unit of 
Gastroenterology of Molinette Hospital (with a mean of 2000 test performed per year70), several 
interesting data, were reported. First, an azithromycin-based triple therapy is not different from a 
clarithromycin-based triple therapy.
71
 Second, a clarithromycin plus metronidazole-based triple therapy 
give similar results than a triple therapy based on a standard dose of PPI, amoxicillin and 
clarithromycin or metro- or tinidazole.
72
 Third, the use of amoxicillin plus clavulanic acid-based triple 
therapy is not different of a CAO regimen.
73 
Fourth, considering a triple therapy based on PPI, 
amoxicillin and tetracycline, the overall H. pylori eradication rate was 53%.
73 
When compared with the  
amoxicillin plus clarithromycin or plus metronidazole or tinidazole regimens, a significant 
Page 23 of 38 
PE
ER
 RE
VIE
W 
CO
PY
 
 
 
 
 
 
 
 
 
Mi
ne
rva
 G
str
oe
nte
rol
og
ica
 e 
Die
tolo
gic
a
Minerva Gastroenterologica e Dietologica
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
66 
67 
68 
69 
70 
81 
82 
83 
84 
85 
86 
87 
88 
89 
90 
91 
92 
93 
94 
95 
23 
 
disadvantage was observed versus the metronidazole- (P = 0.04) but not versus the tinidazole- (P = 
0.08) and the clarithromycin-based regimens (P = 0.11).74 Fifth, the efficacy of a triple therapy based 
on ranitidine bismuth citrate, amoxicillin and clarithromycin, is not more effective than a CAO 
regimen.
75 
Sixth, the efficacy of the ampicillin-based triple therapy for H. pylori eradication remains 
unclear.
76 
Seventh, a one-week PPI, cefixime plus metronidazole based triple therapy gave similar 
results than a MAO regimen.
77 
Eighth, the success rate of a one-week cefixime plus clarithromycin 
based triple therapy was not different from that of the CAO regimen.
78 
   In 2015 Ribaldone et al., to asses the change over time of antibiotic efficacy, prospectively evaluated 
the H. pylori eradication rate of consecutive naïve patients, treated for H. pylori with a standard dose of 
PPI, amoxicillin 1 g and clarithromycin 500 mg twice daily.79 Furthermore, results were compared with 
the randomized prospective study conducted 10 years earlier with the same schedule.
66
 Eradication of 
H. pylori infection was assessed by UBT. The cohort included 182 patients, 99 of them received a 1-
week regimen (group I) and 83 were treated with a 10-day regimen (group II). The overall H. pylori 
eradication rate was 71% in group I and 73% in group II, without significant difference between the 2 
regimens.
78
 When compared with the prospective study published in the year 2002, no difference was 
observed between the groups (P = 0.87 and P = 0.9, respectively).
69
 Thus, in Piedmont, a 
clarithromycin-based treatment regimen was equally effective than 10 years earlier. Nevertheless, these 
eradication rates were significantly inferior than those reported 17 years before.63 In the same context, 
the authors evaluated prospectively the H. pylori eradication rate of consecutive naïve patients, treated 
with a triple therapy comprising a standard dose of PPI, amoxicillin 1 g and metronidazole 500 mg 
twice daily. The cohort included 39 patients treated with a a 1-week regimen (group I) and 27 treated 
with a 10-day regimen (group II). The H. pylori eradication rate was 69% in group I and 70% in group 
II (P = 0.96).
80 
When compared with the prospective study published in the year 2002 no differences 
were observed in the effectiveness of therapy (P = 0.81 for 7 days and P = 0.95 for 10 days).68 Thus, in 
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Piedmont, a metronidazole-based treatment regimen for H. pylori eradication, although unsatisfactory, 
is as effective as 10 years ago. 
 
Table 1     
 
Relapse and reinfection  
   In 1996, Bruno et al.
 
in a cohort of patients with DU in whom H. pylori had been eradicated, showed 
that reinfection occurred in 14.8% of patients between month 2 and month 6, in 5.4% between month 6 
and month 12, and in 11.1% between month 12 and month 24. Active antral gastritis at month 2 was 
found in 19% of the patients converting to H. pylori positivity at month 6, but only in 3.4% of the 
patients in whom eradication still persisted at month 6 (P = 0.02).
81
Although limited by the tests used ( 
urease test and histology), this study has the advantage of a regular follow-up. 
   In another study, using histology, serology and UBT, the authors showed that none of the 108 
patients with history of DU, followed up during the average period of 24 months, had a reinfection. 
Five patients (4.6%) had a DU recurrence (none due to NSAIDs).
82 
These findings provided further 
evidence that the cure of H. pylori infection allows for a dramatic reduction in the frequency of DU 
recurrences, and that the reinfection in adults is unlikely in their population. The different results of 
these two studies81,82 could be explained by the potential relapse risk in the former and the exclusion of 
reinfection in the latter. The robustness of the second is witnessed by the fact that reinfection should be 
confirmed by the positivity of at least two tests.   
 
Conclusions 
 
In Piedmont, in the last 25 years an intense research on clinical aspects of H.pylori infection has been 
conducted. Nevertheless, several aspects of basic research have been approached, with the first 
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description of Helicobacter sequences in the liver of patients with HCC. The actual practical challenge, 
based on data of antibiotic resistance, is the application of the Maastricht V/Florence Guidelines, with 
in Countries with high clarithromycin-resistance rates, as in our region, recommended the bismuth-
containing quadruple therapy as first choice of treatment.
27,83
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Table 1. Studies evaluating efficacy of H. pylori therapy in Piedmont 
 
Author Year of 
publicatio
n 
Origin 
of 
patients 
Diagnosi
s 
Treatment Day
s 
# 
patients 
Eradicatio
n 
diagnosis 
Eradicatio
n 
Di 
Napoli 
et al.
4 
1992 S. Vito 
Hospita
l Turin 
G CBS 120 
mg/6 h + 
Ti 500 
mg/12 h + 
Am 1g/12 
h 
10 48 H 69% 
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CBS 120 
mg/6 h + 
    28 
 
 
 
 
 
Am 1 g/12 
h + Ti 500 
mg/12 h 
    13 
 
 
  22 
 
 
59% 
 
 
Of 300 
mg/12 h 
    11 
 
  27 
 
59% 
 
Of 300 
mg/12 h 
+ Am 500 
mg/12 h 
    11 
  
 
 
  31 
 
 
 
58% 
 
 
 
Bologn
a et 
al.
62 
1992 Molinet
te 
/ 
Cuorgn
è 
DU, Dy 
M 500 
mg/8 h 
    11   43 
H 
72% 
Suriani 
et al.7 
1996 Rivoli / 
Valdese 
DU R 150 
mg/24 h + 
M 500 
mg/6 h + 
Do 100/24 
h + CBS 
300 mg/6 
h 
    14 16 H 81% 
    10 
 
 
     
     
  16 
 
 
  
93% 
 
 
 
Cl 250 
mg/8 h + 
Am 500 
mg/6 h + 
Om 20 
mg/12 h     14   39 95% 
Pellica
no et 
al.
63
 
1997 Molinet
te 
DU 
M 250 
mg/8 h + 
Am 500 
mg/6 h + 
    10 
 
 
     
  26 
 
 
   
H, IgG 
88% 
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28 
29 
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31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
66 
67 
68 
69 
70 
81 
82 
83 
84 
85 
86 
87 
88 
89 
90 
91 
92 
93 
94 
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Om 20 
mg/12 h 
    14   45 89% 
RBC 400 
mg/12 h + 
Cl 500 
mg/12 h 
    28 
 
      7 
 
  40 
 
 
 
80% 
 
 
 
RBC 400 
mg/12 h + 
Cl 500 
mg/12 h + 
Am 1 g/12 
h 
    28 
 
      7 
  40 88% 
 
Lomba
rdo et 
al.
64 
1999 Maurizi
ano 
G L 30 
mg/24 h + 
Am 1 g/12 
h +  
Az 500 
mg/24 h 
      7 
 
 
      3 
 
  37 UBT 54% 
CBS 240 
mg/6 h + 
Om 20 
mg/24 h 
    14   10 67% Franzin 
et al.
59
 
2000 SGAS GU, DU 
Om 20 
mg/12 h + 
Am 1 g/12 
h + Cl 500 
mg/12 h 
      7   39 
H 
90% 
      7 812 72% Am + Cl + 
PPI     14 188 78% 
      7   23 61% 
Della 
Monica 
et al.65, 
66
 
2002 Primary 
care 
Dy,  
GERD, 
PUD, ? Am + M + 
PPI     14     7 
UBT 
86% 
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35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
66 
67 
68 
69 
70 
81 
82 
83 
84 
85 
86 
87 
88 
89 
90 
91 
92 
93 
94 
95 
35 
 
      7   62 71% Am + Ti + 
PPI     14   14 79% 
      7   46 61% Cl + M + 
PPI     14     4 50% 
      7   91 76% Cl + Ti + 
PPI     14     8 75% 
Rocco 
et al.
11 
2002 Rivoli DU Om 40 
mg/12 h + 
Am 1 g/12 
h + Cl 500 
mg/12 h 
      ?   38  63% 
      7   66 68% 
    10   42 76% 
Palmas 
et al.67 
2002 Molinet
te 
DU PPI 20 
mg/12 h + 
Cl 500 
mg/12 h + 
Am 1 g/12 
h 
    14   64 
H, UBT 
72% 
      7 
 
  53 74% 
 
 
    10   50 76% 
Pellica
no et 
al.
68
 
2002 Molinet
te 
DU PPI 20 
mg/12 h + 
Am 1 g/12 
h + M 500 
mg/12 h     14   50 
H, UBT 
78% 
PPI 20 
mg/12 h + 
      7 
 
 
 
 
 
      7   30 77% 
    10   26 77% 
Am 1 g/12 
h + M 250 
mg/8 
    14   32 78% 
      7   27 74% 
Berrutt
i et 
al.69 
2008 Molinet
te 
Indicatio
ns as 
recomme
nded by 
Maastric
ht 2 
Am 1 g/12 
h + Ti 500 
    10   26 
UBT, H 
77% 
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40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
66 
67 
68 
69 
70 
81 
82 
83 
84 
85 
86 
87 
88 
89 
90 
91 
92 
93 
94 
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mg/12 h     14   27 78% 
      7   13 54% 
    10   11 64% 
    14   23 70% 
Pellica
no et 
al.
71
 
2008 Primary 
care 
PUD, G PPI + Am 
1 g/12 h + 
Az 500 
mg/24 h 
    15   12 
UBT 
67% 
      7 
 
       
 
  20 
 
  
 
70% 
 
Berrutt
i et 
al.
72 
2010 Primary 
care 
PUD, G PPI 20 
mg/12 h + 
M 250 
mg/8 + Cl 
500 mg/12 
h 
    14   42 
UBT 
74% 
      7 
      
 
 
  28 
   
 
 
79% 
 
 
Berrutt
i et al
73
 
2010 Primary 
care 
PUD, G PPI 20 
mg/12 h + 
Cl 500 
mg/12 h + 
AmC 1 
g/12 h 
    14   14 
UBT 
79% 
Pellica
no et 
al.74 
2011 Primary 
care 
? PPI 20 
mg/12 h + 
Am 1 g/12 
h + Te 500 
mg/8 h 
      7   40 UBT 53% 
Cisarò 
et al.
75 
2011 Primary 
care 
? RBC 400 
mg/12 h + 
Cl 500 
mg/12 h + 
Am 1 g/12 
h 
      7    67 UBT 67% 
Adriani 
et al.
77 
2013 Primary 
care 
? M + PPI + 
Ce 200 
      7      24 UBT  
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47 
48 
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50 
51 
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53 
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55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
66 
67 
68 
69 
70 
81 
82 
83 
84 
85 
86 
87 
88 
89 
90 
91 
92 
93 
94 
95 
37 
 
mg/12 h 63% 
Ce 400 
mg/12 h 
      7 71% 
Cl + PPI + 
Ce 200 
mg/12 h 
    
 
    34 
 
 
71% 
Fagoon
ee et 
al.
78 
2013 Primary 
care 
? 
Ce 400 
mg/12 h 
      7 
    15 
UBT 
73% 
      7     99 71% Ribald
one et 
al.
79 
2015 ? ? PPI + Am 
1 g/12 h + 
Cl 500 
mg/12 h 
    10     83 
UBT 
73% 
    7 39 69% Ribald
one et 
al.80 
2017 ? ? PPI + Am 
1 g /12 h + 
M 500 
mg/12 h 
   10 27 
UBT 
70% 
DU, duodenal ulcer; Dy, dyspepsia; CBS, colloidal bismuth subcitrate; Am, amoxicillin; Ti, 
tinidazole; Of, ofloxacin; M, metronidazole; H, histology; R, ranitidine; Do, doxycycline; Te, 
tetracycline; F, floxacine; Om, omeprazole; G, gastritis; Cl, clarithromycin; IgG anti-H. pylori; 
PUD, peptic ulcer disease; Du, duodenitis; UBT, urea breath test; RBC, ranitidine bismuth 
subcitrate; L, lansoprazole; Az, azithromycin; RUT, rapid urease test; Cu, culture; SGAS, San 
Giovanni Antica Sede; GU, gastric ulcer; PPI, Proton Pump Inhibitors; GERD, gastroesophageal 
reflux disease; ?, unreported; ATB, antibiotic;  AmC, amoxicillin and clavulanic acid; Ce, cefixime. 
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